Clinical trial
Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers
NCT00381641 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 29, 2006
- Completion date
- December 10, 2024
- Enrollment
- 63 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.
differentiated thyroid gland carcinoma, recurrent thyroid gland carcinoma, refractory thyroid gland carcinoma, stage iii thyroid gland follicular carcinoma ajcc v7, stage iii thyroid gland medullary carcinoma ajcc v7, stage iv thyroid gland follicular carcinoma ajcc v7, stage iv thyroid gland medullary carcinoma ajcc v7, stage iv thyroid gland papillary carcinoma ajcc v7, stage iva thyroid gland follicular carcinoma ajcc v7, stage iva thyroid gland medullary carcinoma ajcc v7, stage iva thyroid gland papillary carcinoma ajcc v7, stage ivb thyroid gland follicular carcinoma ajcc v7, stage ivb thyroid gland medullary carcinoma ajcc v7, stage ivb thyroid gland papillary carcinoma ajcc v7, stage ivc thyroid gland follicular carcinoma ajcc v7, stage ivc thyroid gland medullary carcinoma ajcc v7, stage ivc thyroid gland papillary carcinoma ajcc v7, thyroid gland oncocytic carcinoma, unresectable thyroid gland carcinoma